Home Cart Sign in  
Chemical Structure| 2439-02-3 Chemical Structure| 2439-02-3

Structure of Kynurenic acid sodium
CAS No.: 2439-02-3

Chemical Structure| 2439-02-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also a selective ligand of the GPR35 receptor.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Kynurenic acid sodium

CAS No. :2439-02-3
Formula : C10H6NNaO3
M.W : 211.15
SMILES Code : O=C(C1=NC2=CC=CC=C2C(O)=C1)[O-].[Na+]
MDL No. :MFCD12195841

Safety of Kynurenic acid sodium

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human umbilical cord-derived MSCs (hUC-MSCs) 200 μM 24 hours To investigate the effect of KYN on TSG-6 expression, results showed that KYN had no significant effect on TSG-6 expression. Cell Death Differ. 2018 Jul;25(7):1209-1223
Human umbilical cord-derived MSCs (hUC-MSCs) 50 μM 24 hours To investigate the effect of KYNA on TSG-6 expression, results showed that KYNA significantly increased TSG-6 mRNA and protein levels. Cell Death Differ. 2018 Jul;25(7):1209-1223
human IPS-derived cardiomyocytes 20 μM 1 hour To investigate the protective effects of KynA in simulated ischemia-reperfusion injury, results showed that KynA improved cell survival in a GPR35-dependent manner. Science. 2022 Aug 5;377(6606):621-629
murine neonatal cardiomyocytes 20 μM 20 minutes To investigate the activation of GPR35 by KynA and its effects on mitochondria, results showed that KynA promoted the colocalization of GPR35 with mitochondrial proteins. Science. 2022 Aug 5;377(6606):621-629
Rat cortical astrocytes 5 or 25 μM 12 hours KYNA significantly attenuated the immunoreactivity of C3 and GFAP induced by gp120 and inhibited the expression of A1-specific genes and the release of pro-inflammatory cytokines. J Neuroinflammation. 2023 Mar 30;20(1):87

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C. elegans Wildtype and mutant C. elegans Supplementation in the feeding media 100 µM or 2.5 mM After 2 hr of fasting and subsequent refeeding Fasting results in a depression of KynA levels, which then permits the hyperactive feeding state when animals are returned to food. As food is ingested, KynA levels recover, attenuating the hyperactive feeding behavior. Cell. 2015 Jan 15;160(1-2):119-31
BALB/c mice LPS-induced acute lung injury (ALI) model Intravenous injection 200 μM 48-hour pretreatment before injection To investigate the effect of KYNA pretreatment on the therapeutic efficacy of MSCs in ALI, results showed that KYNA pretreatment significantly reduced the number of infiltrated cells and neutrophils in the lung. Cell Death Differ. 2018 Jul;25(7):1209-1223
Mice Cardiac ischemia/reperfusion (I/R) injury model Intraperitoneal injection 5 mg/kg Single dose 2 hours or 24 hours prior to ischemia To investigate the protective effects of KynA on cardiac ischemia-reperfusion injury, results showed that KynA significantly reduced myocardial infarct size, and this protection was dependent on GPR35. Science. 2022 Aug 5;377(6606):621-629

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.74mL

0.95mL

0.47mL

23.68mL

4.74mL

2.37mL

47.36mL

9.47mL

4.74mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories